# OnCo record salivary-duct-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/salivary-duct-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "salivary-duct-carcinoma" ;
  schema:name "Salivary duct carcinoma"@en ;
  schema:alternateName "SDC"@en, "High-grade salivary duct carcinoma"@en, "Androgen receptor-positive salivary carcinoma"@en ;
  schema:description "Salivary duct carcinoma is an aggressive cancer of the parotid gland that behaves like a high-grade breast cancer and carries the same switches: most tumours run on the androgen receptor and about a third on HER2, so hormone blockers borrowed from prostate cancer and trastuzumab borrowed from breast cancer now shrink many of them."@en ;
  schema:url <https://onco.cc/cancers/salivary-duct-carcinoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Salivary_duct_carcinoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Salivary_duct_carcinoma> ;
  onco:tag "subtype-page", "head-and-neck" ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bernier-eortc-22931-nejm-2004/>, <https://onco.cc/key-papers/paper-laurie-licitra-salivary-systemic-jco-2006/>, <https://onco.cc/key-papers/paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019/>, <https://onco.cc/key-papers/paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018/> ;
  onco:pipeline <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/apalutamide/>, <https://onco.cc/trials/nct04325828/>, <https://onco.cc/drugs/enzalutamide/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/targets/her2/>, <https://onco.cc/drugs/leuprolide/>, <https://onco.cc/drugs/bicalutamide/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/apalutamide/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/trials/nct04325828/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/> .